HDAC9 and melanoma: However, the pharmacological toxicity experiment reveals that the IC50 of pan-HDAC inhibitor panobinostat is much lower in peripheral blood mononuclear cells (PBMCs) than that in melanoma cells, indicating that HDAC inhibitor is cytotoxic in PBMCs at concentrations much lower than those required for melanoma antitumor activity (104).